Trials / Completed
CompletedNCT01734278
Observational Post-Authorisation Safety Study of Asenapine (Sycrest)
An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- Professor Saad Shakir · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to evaluate the use and short term safety of Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the manufacturer of Sycrest.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is a non-interventional study. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2017-01-01
- Completion
- 2018-01-01
- First posted
- 2012-11-27
- Last updated
- 2018-07-31
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01734278. Inclusion in this directory is not an endorsement.